For the quarter ending 2026-03-31, FHTX made $3,267K in revenue. -$20,032K in net income. Net profit margin of -613.16%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 3,267 | 6,450* | 8,153 | 558* |
| Research and development | 18,259 | 24,236* | 20,002 | 25,395* |
| Gain on lease modification | - | 408* | - | - |
| Impairment of long-lived assets | - | 5,914* | 0 | -4,796* |
| General and administrative | 6,581 | 7,594* | 6,652 | 6,915* |
| Total operating expenses | 24,840 | 37,336* | 26,654 | 27,514* |
| Loss from operations | -21,573 | -30,886* | -18,501 | -26,956* |
| Interest income | 1,742 | 2,649* | 2,032 | 2,353* |
| Other income (expense), net | -44 | 1,501* | 620 | 1,136* |
| Total other income, net | 1,698 | 4,150* | 2,652 | 3,489* |
| Loss before income taxes | - | - | - | -23,468 |
| Net loss | -19,875 | -26,736* | -15,849 | -23,468* |
| Unrealized gaines on marketable securities | -157 | -315 | 68 | -324 |
| Total other comprehensive gain | -157 | -315* | 68 | -324* |
| Total comprehensive loss | -20,032 | -27,051 | -15,781 | -23,793 |
| Basic EPS | -0.29 | -0.43 | -0.25 | -0.471 |
| Diluted EPS | -0.29 | -0.43 | -0.25 | -0.471 |
| Basic Average Shares | 69,540,075 | 62,932,625 | 63,029,293 | 50,515,138 |
| Diluted Average Shares | 69,540,075 | 62,932,625 | 63,029,293 | 50,515,138 |
Foghorn Therapeutics Inc. (FHTX)
Foghorn Therapeutics Inc. (FHTX)